Volume Alert - GILD 106.45 Gilead Sciences $GILD H
Post# of 162
Posted On: 11/07/2014 11:41:38 PM
Volume Alert - GILD 106.45 Gilead Sciences $GILD Hit a high today of 108.95 Closing the day 11/07/14 at 106.45 -0.49 -0.46% With a day low of 106.33 and a total volume of 12,663,723.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), GILD: 106.45 (-0.49), AZN: 72.88 (+0.03), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14), CELG: 106.45 (-0.69)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 106.45 (-0.49), MFS.VN: 0.085 (-0.005)
Early Glance: Biotechnology companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Humana Misses On ObamaCare Spending, Hep C Costs
at Investor's Business Daily - Fri Nov 07, 9:32AM CST
Humana (HUM) narrowed its earnings outlook for the year as its third-quarter revenue and earnings views fell short of analyst expectations on insurance and hepatitis C-related costs. Full-year earnings guidance is now in the range of $7.40-$7.60 per...
GILD: 106.45 (-0.49), AET: 82.29 (-2.41), HUM: 130.58 (-9.29)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $108.23
Comtex SmarTrend(R) - Fri Nov 07, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.16 and have already reached the first level of resistance at $108.23. Analysts will be watching for a cross of the next upside pivot targets of $109.51 and $111.86.
GILD: 106.45 (-0.49)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
Linkage Biosciences Adds to Board Leadership
Marketwired - Fri Nov 07, 7:02AM CST
Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company's Board of Directors. The election reflects Linkage's continued focus on expansion in both domestic and international markets.
GILD: 106.45 (-0.49), GHDX: 35.81 (+0.72)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.37 (-0.32), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15)
Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DAL, COP, QCOM, KMI and GILD.
KMI: 38.75 (+0.22), GILD: 106.45 (-0.49), DAL: 42.69 (-0.21), QCOM: 69.26 (-1.32), COP: 72.16 (+0.84)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.45 (-0.49), PFE: 29.92 (-0.12), LH: 100.52 (-2.41), ABBV: 61.50 (-1.21), CVD: 100.52 (-0.58)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
Business Wire - Thu Nov 06, 7:31AM CST
--- First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead -
GILD: 106.45 (-0.49)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), DVA: 74.49 (-3.54), GILD: 106.45 (-0.49), SLXP: 91.47 (-47.08), ICPT: 172.59 (-74.39), HUM: 130.58 (-9.29)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), GILD: 106.45 (-0.49), AZN: 72.88 (+0.03), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14), CELG: 106.45 (-0.69)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 106.45 (-0.49), MFS.VN: 0.085 (-0.005)
Early Glance: Biotechnology companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Humana Misses On ObamaCare Spending, Hep C Costs
at Investor's Business Daily - Fri Nov 07, 9:32AM CST
Humana (HUM) narrowed its earnings outlook for the year as its third-quarter revenue and earnings views fell short of analyst expectations on insurance and hepatitis C-related costs. Full-year earnings guidance is now in the range of $7.40-$7.60 per...
GILD: 106.45 (-0.49), AET: 82.29 (-2.41), HUM: 130.58 (-9.29)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $108.23
Comtex SmarTrend(R) - Fri Nov 07, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.16 and have already reached the first level of resistance at $108.23. Analysts will be watching for a cross of the next upside pivot targets of $109.51 and $111.86.
GILD: 106.45 (-0.49)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
Linkage Biosciences Adds to Board Leadership
Marketwired - Fri Nov 07, 7:02AM CST
Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company's Board of Directors. The election reflects Linkage's continued focus on expansion in both domestic and international markets.
GILD: 106.45 (-0.49), GHDX: 35.81 (+0.72)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.37 (-0.32), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15)
Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DAL, COP, QCOM, KMI and GILD.
KMI: 38.75 (+0.22), GILD: 106.45 (-0.49), DAL: 42.69 (-0.21), QCOM: 69.26 (-1.32), COP: 72.16 (+0.84)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.45 (-0.49), PFE: 29.92 (-0.12), LH: 100.52 (-2.41), ABBV: 61.50 (-1.21), CVD: 100.52 (-0.58)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
Business Wire - Thu Nov 06, 7:31AM CST
--- First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead -
GILD: 106.45 (-0.49)
(0)
(0)Gilead Sciences Inc. (GILD) Stock Research Links
Scroll down for more posts ▼